TY - JOUR
T1 - Associations between drugs and small-bowel mucosal bleeding
T2 - Multicenter capsule-endoscopy study
AU - Niikura, Ryota
AU - Yamada, Atsuo
AU - Maki, Koutarou
AU - Nakamura, Masanao
AU - Watabe, Hirotsugu
AU - Fujishiro, Mitsuhiro
AU - Oka, Shiro
AU - Esaki, Motohiro
AU - Fujimori, Shunji
AU - Nakajima, Atsushi
AU - Ohmiya, Naoki
AU - Matsumoto, Takayuki
AU - Tanaka, Shinji
AU - Koike, Kazuhiko
AU - Sakamoto, Choitsu
N1 - Funding Information:
MITSUHIRO FUJISHIRO HAS received a lecture honorarium from Takeda Parametrical Co., Ltd; Eisai Co., Ltd; Zeria Parametrical Co.; Ltd; and Nihon Parametrical, Co., Ltd and a collaborative fund from HOYA-Pentax Company as a chief investigator of The University of Tokyo. Motohiro Esaki has received a grant support from Mitsubishi Tanabe Pharma Co.; Japan Immunoresearch Laboratories Co., Ltd; Eisai Co., Ltd; and Abbvie GK. Atsushi Nakajima has received a grant support from Ajinomoto Co., Inc.; Astellas Pharma Inc.; Takeda Pharmaceutical Co., Ltd; Mylan N.V.; Otsuka Pharmaceutical Co., Ltd; Biofermin Seiyaku Co., Ltd; and Taisho Pharmaceutical Co., Ltd. Naoki Ohmiya has received a grant support from Ajinomoto Co., Inc.; Japan Immunoresearch Laboratories Co., Ltd; Mitsubishi Tanabe Pharma Corporation; Medical Corporation Fukuyukai; and Eisai Co., Ltd. Takayuki Matsumoto has received a grant support or speaker fees from EA Pharma Co., Ltd; Mitsubishi Tanabe Pharma Corporation; Japan Immunoresearch Laboratories Co., Ltd; Otsuka Pharmaceutical Co., Ltd; Daiichi Sankyo Co., Ltd; Kyorin Pharmaceutical Co., Ltd; Kyowa Hakko Kirin Co., Ltd; and Jansen Pharmaceutical K.K. Shinji Tanaka has received grant support or speaker fees from AstraZeneca K.K.; Otsuka Pharmaceutical Co., Ltd; Daiichi Sankyo Co., Ltd; Eisai Co., Ltd; Mitsubishi Tanabe Pharma Corporation; Zeria Parametrical Co., Ltd; and Asahi Kasei Medical Co., Ltd. Choitsu Sakamoto has received speaker fees from Pfizer Japan Inc.; Astellas Pharma Inc.; and AstraZeneca K.K. The other authors declare no conflicts of interest.
Funding Information:
THIS STUDY WAS partly supported by the Ministry of Health, Labour and Welfare (H23-NI-045) and The Japanese Association for Capsule Endoscopy. The funding agencies had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Publisher Copyright:
© 2017 Japan Gastroenterological Endoscopy Society
PY - 2018/1
Y1 - 2018/1
N2 - Background and Aim: Although several drugs may induce small-bowel mucosal injuries, it is unclear whether these injuries contribute to overt small-bowel bleeding. This study was designed to evaluate the associations between drug use and small-bowel mucosal injury and between these mucosal injuries and overt bleeding in a disease-relevant population. Methods: We retrospectively studied patients with suspected small-bowel diseases who underwent capsule endoscopy between 2010 and 2013. Drug exposure, Charlson Comorbidity Index, smoking, and alcohol consumption were assessed before capsule endoscopy. Adjusted odds ratios (AOR) and confidence intervals (CI) were estimated for small-bowel mucosal injury and small-bowel overt bleeding. Results: In total, 850 patients were analyzed during the study period. Median age was 64 years, and 544 patients (64.0%) were men. Among the patients with small-bowel mucosal injury (n = 60) and without mucosal injury (n = 705), use of non-steroidal anti-inflammatory drugs (NSAIDs) (AOR 1.8, 95% CI 1.01–3.31) was significantly associated with an increased risk of small-bowel mucosal injury compared with non-use. Patients with small-bowel mucosal injury with overt bleeding (n = 85) and without overt bleeding (n = 60) were compared, and no significant difference between the groups in the usage rates for NSAIDs, thienopyridine, other antiplatelets, anticoagulants, acetaminophen, tramadol hydrochloride, or steroids was revealed, even after adjusting for confounders. Conclusion: Although the use of NSAIDs was significantly associated with an increased risk of small-bowel mucosal injury, no significant associations were observed between the use of such drugs and small-bowel overt bleeding.
AB - Background and Aim: Although several drugs may induce small-bowel mucosal injuries, it is unclear whether these injuries contribute to overt small-bowel bleeding. This study was designed to evaluate the associations between drug use and small-bowel mucosal injury and between these mucosal injuries and overt bleeding in a disease-relevant population. Methods: We retrospectively studied patients with suspected small-bowel diseases who underwent capsule endoscopy between 2010 and 2013. Drug exposure, Charlson Comorbidity Index, smoking, and alcohol consumption were assessed before capsule endoscopy. Adjusted odds ratios (AOR) and confidence intervals (CI) were estimated for small-bowel mucosal injury and small-bowel overt bleeding. Results: In total, 850 patients were analyzed during the study period. Median age was 64 years, and 544 patients (64.0%) were men. Among the patients with small-bowel mucosal injury (n = 60) and without mucosal injury (n = 705), use of non-steroidal anti-inflammatory drugs (NSAIDs) (AOR 1.8, 95% CI 1.01–3.31) was significantly associated with an increased risk of small-bowel mucosal injury compared with non-use. Patients with small-bowel mucosal injury with overt bleeding (n = 85) and without overt bleeding (n = 60) were compared, and no significant difference between the groups in the usage rates for NSAIDs, thienopyridine, other antiplatelets, anticoagulants, acetaminophen, tramadol hydrochloride, or steroids was revealed, even after adjusting for confounders. Conclusion: Although the use of NSAIDs was significantly associated with an increased risk of small-bowel mucosal injury, no significant associations were observed between the use of such drugs and small-bowel overt bleeding.
UR - http://www.scopus.com/inward/record.url?scp=85041292602&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041292602&partnerID=8YFLogxK
U2 - 10.1111/den.12922
DO - 10.1111/den.12922
M3 - Article
C2 - 28719079
AN - SCOPUS:85041292602
SN - 0915-5635
VL - 30
SP - 79
EP - 89
JO - Digestive Endoscopy
JF - Digestive Endoscopy
IS - 1
ER -